Table 1

Stages of the scoping reviews

1. Research question identified	1.1. Overarching goal	To explore the depth and breadth of evidence for the indications, epidemiology, genetics, efficacy and safety of drugs that act on JAK/STAT pathway in the treatment of patients with dermatological diseases.
	1.2. Research question	What are the indications, epidemiology, genetics, efficacy and safety of drugs that act on JAK/STAT pathway in the treatment of dermatological diseases?
	1.3. Purposes of this scoping review	1.3.1. Review the evidence of indications for drugs that act on JAK/STAT pathway in the treatment of dermatogical diseases.
		1.3.2. Review the evidence of epidemiology of drugs acting on JAK/STAT pathway in the treatment of dermatogical diseases.
		1.3.3. Review the evidence of genetics of drugs acting on JAK/STAT pathway in the treatment of dermatogical diseases.
		1.3.4. Review the evidence on efficacy of the drugs that act on JAK/STAT pathway in the treatment of dermatogical diseases.
		1.3.5. Review the evidence on safety of drugs that act on JAK/STAT pathway in the treatment of dermatogical diseases.
		1.3.6. Obtain concrete research questions that can be answered through a systematic review.
		1.3.7. Identify research gaps in the existing literature.
2. Identifying relevant literature	2.1. We will perform a three-step search	2.1.1. First search: an initial limited search of the MEDLINE and EMBASE databases to find keywords in the title, abstract and the index terms used to describe the articles.
		2.1.2. Second search: a search of MEDLINE and EMBASE using all identified keywords. Additionally, CINAHL, Scopus and Web of Science to the search engines will be searched in this second step.
		2.1.3. Third search: the reference lists of all identified reports and articles will be searched for additional studies.
	2.2. We will include the studies published in full text in English until October 2018.
	2.3. We will contact authors, of primary studies or reviews, for further information, if this is relevant.
	2.4. The search and selection will be done by at least two reviewers and in case of disagreement will be decided by agreement with a third reviewer.
3. Selecting studies	3.1. Inclusion criteria	3.1.1. We will include in the review the studies on the human use of drugs inhibitors of JAK/STAT pathway published on the topics: indications, epidemiology, genetics, efficacy and safety.
		3.1.2. Design of the studies: we will include guidelines, systematic reviews, randomised clinical trials, observational studies, cross sectional case report and series.
	3.2. Exclusion criteria	3.2.1. We will exclude narrative reviews and studies performed in vitro or using animal models.
4. Charting the data	4.1. We will extract the data in a predefined form.
	4.2. From each study we will extract title, objective, main variables related to patients, intervention, comparator, outcomes (efficacy and safety) and bibliographic data.
	4.3. We will classify the studies by treatment indication.
	4.4. The list of studies, variables and data of there view will be published in an online file.
	4.5. The data collection will be done by at least two reviewers and in case of disagreement will be decided by agreement with a third reviewer.
5. Collating, summarising and reporting results	5.1. The results of comprehensive search will be presented using the PRISMA flow diagram.
	5.2. We will synthesise qualitatively the evidence obtained ordering it by topics: indications, mechanism of action, efficacy and safety of drugs that act on JAK/STAT pathway to treat dermatological diseases and we will present it in a diagrammatic tabular form and in a descriptive format.
	5.3. We will use the extension of PRISMA for scoping review for the notification of the review.
6. Differences between the protocol and the overview	Any changes in the methodology that need to be carried out throughout the study will be detailed together with the results publication.

JAK/STAT, Janus kinase and Signal Transducer and Activator of Transcription protein; PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses.